Clinical trial NCT04904432: PLIN1 Variants in Precocious ACS (SCAPLIN)
Official title: Involvement of Perilipin-1 Variants in Precocious Acute Coronary Syndrome
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Coronary Syndrome
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2021-05-27
Enrollment: 200
Sex: ALL
Minimum age (years): 10
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study aims to identify a genetic predisposition factor of precocious acute coronary syndrome occurrence (ACS). ACS is a major public health problem and the first cause of mortality in the world. It can be due to several risk factor such as heredity. the investigators make the hypothesis that occurrence of early ACS (defined as \<50yo for men and \<55yo for women) could be the initiatory event of a mild form of genetic lipodystrophy . Our previous study shown an occurrence risk of ACS about 8.3 in patients carrying a mutation in the PLIN1 gene versus patients without a mutation. The PLIN1 gene encode for perilipin 1 protein localized on the lipid droplet surface. This protein phosphorylation activates the triglycerides lipolysis. Our goals in this study are multiple: to validate the high frequency of mutations in this gene in patients with early ACS, to determine differences in triglycerides metabolism and also relapse rate between carrier and non-carrier patients of mutation in PLIN1. Our first aim will be to carry out the inclusion of 200 patients with precocious ACS. This will allow us to obtain around 15 patients carrying a mutation in the PLIN1 gene based on our previous study. the investigators will reprogramme patients' cells (carrying or not a PLIN1 mutation) in human Induce Pluripotent Stem cells (hIPSc). These hIPSc will be differentiated in cell types of interest as adipocytes or macrophages. the investigators will then study triglycerides metabolism (lipid droplet formation, localization and phosphorylation of perlipin 1) in these cells and atheroma plaque formation. Finally, the investigators will study clinical data such as relapse rate and searching for correlation with PLIN1 mutation.


Eligibility criteria: Inclusion Criteria:

* Age of the patient when ACS occurs (between 18 and 50yo for men, between 18 and 55yo for women)
* Written informed consent

Exclusion Criteria:

* Men \<18yo or \>50yo
* Women \<18yo or \>55yo
* ACS causes (toxic, coronary dissection)
* Congenital cardiac malformations
* Familial hypercholesterolaemia
* Pregnancy, breast-feeding women or vulnerable profile.
* Patient refusal to participate or previously included in a clinical research trial.

Primary outcomes:
measure: PLIN1 mutation
timeFrame: 1 month
measure: Lipid droplets
timeFrame: 3 years
Secondary outcomes:
measure: relapse rate
timeFrame: 1 year
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Hôpitaux de Marseille
Study officials:
affiliation: Assistance Publique Hôpitaux de Marseille
name: Emilie GARRIDO-PRADALIE
role: STUDY_DIRECTOR
References: